BMRN - Company ID 0001048477
The table below shows BIOMARIN PHARMACEUTICAL INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B |
| Cost of revenue | $717.44M | $580.24M | $532.06M | $503.02M | $470.51M | $524.27M |
| Gross profit | - | - | - | - | - | - |
| R&D | $921.93M | $747.18M | $746.77M | $649.61M | $628.79M | $628.12M |
BIOMARIN PHARMACEUTICAL INC reported annual revenue of $3.22B for fiscal year 2025. That is up 12.9% from $2.85B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.12B (FY 2016) to $3.22B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $1.15B |
| $1.01B |
| $892.41M |
| $823.24M |
| $759.38M |
| $737.67M |
| Operating income | $409.48M | $484.21M | $185.77M | $160.97M | -$82.34M | -$43.44M |
| Income tax | $133.58M | $114.90M | $20.92M | $8.02M | -$11.27M | -$903.03M |
| Net income | $348.90M | $426.90M | $167.60M | $141.60M | -$64.10M | $854.03M |
| EPS (diluted) | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 | $4.50 |